For patients with severe eosinophilic asthma, Nucala helps to reduce exacerbations, including those requiring hospitalisations6,10,11
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Nucala offers proven asthma control and can help reduce OCS use for your patients with severe eosinophilic asthma1,2
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
June 2022 | PM-GB-MPL-WCNT-220002 (V1.0)